The Myogenes Clozapine Test
Developed in collaboration with Prof. David Taylor, the clozapine genetic test is for use in the treatment of schizophrenia.
An easy to administer simple saliva test that looks at evidence based genes associated with a patient’s response to clozapine.
Only Available through a Clinician
The Myogenes Clozapine Test
Developed in collaboration with Prof. David Taylor, the clozapine genetic test is for use in the treatment of schizophrenia.
An easy to administer simple saliva test that looks at evidence based genes associated with a patient’s response to clozapine.
Only Available through a Clinician
This test is for…
All people for whom clozapine is being considered plus:
- People with schizophrenia.
- Current clozapine patients who cannot achieve a therapeutic level despite high dose clozapine.
- Inadequate response to treatment despite the sequential use of adequate doses of at least 2 different antipsychotic drugs: at least 1 of the drugs should be a non-clozapine second-generation antipsychotic.
In addition, patients already receiving clozapine:
- Patients with only a partial treatment response.
- Patients where neutrophil counts necessitate interruption of treatment.
- Patients with possible benign ethnic neutropenia but their status is uncertain.
This test is for…
All people for whom clozapine is being considered plus:
- Current clozapine patients whose BEN status is unknown.
- Current clozapine patients who cannot achieve a therapeutic level despite high dose clozapine.
- Inadequate response to treatment despite the sequential use of adequate doses of at least 2 different antipsychotic drugs: at least 1 of the drugs should be a non-clozapine second-generation antipsychotic
In addition, patients already receiving clozapine:
- Patients with only a partial treatment response
- Patients where neutrophil counts necessitate interruption of treatment
- Patients with possible benign ethnic neutropenia but their status is uncertain
There are 24 million people in the world with treatment resistant schizophrenia (TRS)
Clozapine is the only effective treatment for TRS but is massively underused due to risk of adverse reactions.
The Myogenes Clozapine Test can minimise these risks, free up hospital beds, and save the NHS billions of pounds.
There are 24 million people in the world with treatment resistant schizophrenia (TRS)
Clozapine is the only effective treatment for TRS but is massively underused due to risk of adverse reactions.
The Myogenes Clozapine Test can minimise these risks, free up hospital beds, and save the NHS billions of pounds.
NICE Guidelines:
Adults with schizophrenia not responding to at least 2 antipsychotics should be offered clozapine.
However, clozapine is grossly underused whilst being the ONLY approved treatment for treatment-resistant schizophrenia.
NICE Guidelines:
Adults with schizophrenia not responding to at least 2 antipsychotics should be offered clozapine.
However, clozapine is grossly underused whilst being the ONLY approved treatment for treatment-resistant schizophrenia.
Ethnic minority groups are less likely to receive clozapine
This is owing to benign ethnic neutropenia (BEN), prevalent in ethnic minority groups.
If you belong to an ethnic minority group, you are less likely to receive clozapine resulting in higher hospitalisation and mortality.
HOW TO GET A TEST
Contact us now to arrange your test
Office hours are:
9:00am – 5:30pm
Monday – Friday
We will call you back
within these hours
Office hours are:
9:00am – 5:30pm
Monday – Friday
We look forward to hearing from you soon